Bank of Nova Scotia has beaten earnings estimates four quarters in a row with strong margins and a breakout setup, but the price is 15.8% above the analyst target and quality is below average.
Thesis pillars
- Strong Margins No Moat→Stable
- Price Above Analyst Target→Stable
- Perfect Earnings Beat Streak↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026
Bank Nova Scotia Halifax Pfd 3 (BNS) Stock Analysis
Breakout setup · Catalyst-Driven edge
Financial Services · Banks - Diversified
Hold if already holding. Not a fresh buy at $93.66, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.6% away).
The Bank of Nova Scotia provides various banking products and services in Canada, the United States, Mexico, Peru, Chile, Colombia, the Caribbean and Central America, and internationally. It operates through Canadian Banking, International Banking, Global Wealth Management, and... Read more
Hold if already holding. Not a fresh buy at $93.66, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.6% away). Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Mixed signals. Hold existing position. Score 5.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 28d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Nov 3, 2026Recent Developments — Bank Nova Scotia Halifax Pfd 3
Latest news
- NEWS Scotiabank Maintains Cheniere Energy at Sector Outperform — fiscal.ai Nov 3, 2026 neutral
- NEWS Scotiabank Upgrades Ero Copper to Sector Outperform — fiscal.ai Nov 3, 2026 neutral
- NEWS Scotiabank Commentary on Bank of Canada Governor's Testimony — fiscal.ai Nov 3, 2026 neutral
- NEWS Scotiabank Adjusts Price Target on Vertex Pharmaceuticals — fiscal.ai Nov 3, 2026 neutral
- NEWS Scotiabank Adjusts Price Targets for Gilead Sciences and Eli Lilly — fiscal.ai Nov 3, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-04T11:49:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $93.66, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.6% away). Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Mixed signals. Hold existing position. Analyst target $78.44 reached (−16.2%), stop $90.88 (−3.1%), A.R:R -2.1:1. Score 5.5/10, moderate confidence.
Analyst target $78.44 reached (−16.2% from $93.66); no take-profit level is published. Analyst target $78.44 reached (−16.2%), stop $90.88 (−3.1%), A.R:R -2.1:1. Stop-loss: $90.88.
Analyst target reached - limited upside remaining; Near 52-week high (2.6% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9).
Bank Nova Scotia Halifax Pfd 3 trades at a P/E of 17.0 (forward 13.8). TrendMatrix value score: 6.8/10. Verdict: Hold.
19 analysts rate BNS, with a consensus score of 3.6/5. 3 analysts publish price targets averaging $92.
What does Bank Nova Scotia Halifax Pfd 3 do?The Bank of Nova Scotia provides various banking products and services in Canada, the United States, Mexico, Peru,...
The Bank of Nova Scotia provides various banking products and services in Canada, the United States, Mexico, Peru, Chile, Colombia, the Caribbean and Central America, and internationally. It operates through Canadian Banking, International Banking, Global Wealth Management, and Global Banking and Markets segments. The company offers financial advice and solutions, and banking products, including debit and credit cards, chequing and saving accounts, investments, mortgages, loans, and insurance to individuals; and retail automotive financing solutions. It also provides business banking solutions comprising lending, deposit, cash management, and trade finance solutions to small, medium, and large businesses. In addition, it provides wealth management advice and solutions, including online brokerage, mobile investment, full-service brokerage, trust, private banking, and private investment counsel services; and retail mutual funds, exchange traded funds, liquid alternatives, and institutional funds. The company was founded in 1832 and is headquartered in Toronto, Canada.